Business Wire

VA-HILTON

11.1.2021 06:12:36 CET | Business Wire | Press release

Share
With Pent Up Demand Expected in 2021, Hilton Introduces Hilton EventReady Hybrid Solutions for Meetings and Events

As we emerge from a year of uncertainties, one business reality seems crystal clear: Hybrid meetings and events will be critical in the near-term. To address this dramatic shift in how people meet and celebrate, Hilton is introducing a set of Hilton EventReady Hybrid Solutions. The new suite of offerings, which will continue to evolve, directs event planners to Hilton’s hybrid-ready hotels while also providing them with planning resources – including an expanded Hilton EventReady Playbook and flexible customer offers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210110005058/en/

With each meeting and event experience delivered by dedicated team members, as part of the Hilton EventReady Hybrid Solutions, participating hotels will have access to comprehensive team member training resources to build and strengthen their knowledge in hybrid events.

“Hilton has remained a leader in the meetings and events industry for more than 100 years by listening intently and innovating quickly to changing customer needs,” said Martin Rinck, executive vice president and chief brand officer, Hilton. “Hilton EventReady Hybrid Solutions were born out of our continued commitment to excellence – from accessing the capabilities of our global portfolio to rolling out a suite of extensive event planner resources and introducing team member training to ensure we can deliver the optimum overall event experience.”

The Hilton EventReady Hybrid Solutions will begin rolling out globally this month. Additionally, the expanded Hybrid Events chapter of the Hilton EventReady Playbook which will include detailed case studies , pro-tips, a glossary of hybrid event terms and more – will also be available in English this month and accessible to customers working with any hotel within the Hilton global portfolio.

The portfolio of hybrid-ready hotels will spotlight the baseline requirements that customers should expect when hosting a small hybrid event, which include:

  • IT Readiness: Each hotel will have undergone an evaluation to assess the available IT bandwidth and infrastructure of the hotel to meet the requirements of small hybrid events. To be deemed “hybrid-ready”, hotels are required to have a minimum amount of incremental and available bandwidth that is above and beyond the hotel’s average circuit utilization level. This requirement allows for seamless communication and connectivity to optimize the hybrid experience within the hotel while providing easy access for virtual attendees.
  • Multi-Site Offering and Express Agreements: These incentives enable customers to book the in-person portion of their event at multiple hybrid-ready Hilton locations as well as create a more seamless contract experience.
  • Expanded Playbook: While the EventReady Playbook is available to customers globally, those looking for in-depth information on planning and executing small hybrid events can access the expanded Hybrid Events chapter, which will continue to evolve alongside customer needs.

As part of the Hilton EventReady Hybrid Solutions, Encore (formerly PSAV) is offering several event technology packages created for small hybrid events at participating hotels in addition to Presentation Stages , a production-ready event solution equipped with critical broadcast technology and staging equipment that helps elevate event messaging and engagement. Presentation Stages offer a clean and safe pre-built location to produce, record and/or broadcast a high-quality online event far exceeding production values available from the typical home or office. The Hilton properties equipped with event technology will accommodate between two to six onsite presenters and up to 50 in-person attendees.

Presentation Stages are currently available to book at Conrad Fort Lauderdale Beach , Hilton Atlanta , Hilton Anatole , Hilton Denver , The Beverly Hilton with several more being made available in Cleveland, Minneapolis, New York, Washington, D.C. and across Europe, Middle East and Africa by the end of the year.

For more information on Hilton EventReady Hybrid Solutions, including a list of the hybrid-ready hotels, visit meetings.hilton.com/eventready .

About Hilton

Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,300 properties with nearly one million rooms, in 118 countries and territories. Dedicated to fulfilling its mission to be the world’s most hospitable company, Hilton has welcomed more than 3 billion guests in its more than 100-year history, earned a top spot on the 2020 World’s Best Workplaces list, and was named the 2019 Global Industry Leader on the Dow Jones Sustainability Indices. In 2020, Hilton CleanStay was introduced, bringing an industry-defining standard of cleanliness and disinfection to hotels worldwide. Through the award-winning guest loyalty program Hilton Honors, the more than 110 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy, plus enjoy instant benefits, including contactless check-in with room selection, Digital Key, and Connected Room. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook , Twitter , LinkedIn , Instagram and YouTube .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye